Zurich Cantonal Bank
AVIR icon

Zurich Cantonal Bank’s Atea Pharmaceuticals AVIR Stock Holding History

Zurich Cantonal Bank’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,955
Closed -$40K – 2805
2023
Q1 		$40K Hold
11,955
– – ﹤0.01% 2636
2022
Q4 		$57.5K Buy
11,955
+1,865
+18% +$9.43K ﹤0.01% 2556
2022
Q3 		$57K Hold
10,090
– – ﹤0.01% 2540
2022
Q2 		$72K Buy
10,090
+6,621
+191% +$45.2K ﹤0.01% 2436
2022
Q1 		$25K Hold
3,469
– – ﹤0.01% 2644
2021
Q4 		$31K Buy
3,469
+680
+24% +$10.6K ﹤0.01% 2818
2021
Q3 		$98K Buy
2,789
+2,693
+2,805% +$74.7K ﹤0.01% 2350
2021
Q2 		$2K Buy
+96
New +$2.88K ﹤0.01% 2600

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Zurich Cantonal Bank's AVIR Position: Q2 2023 in Review

Zurich Cantonal Bank sold out of Atea Pharmaceuticals (AVIR) in Q2 2023, closing a stake of 11,955 shares — an estimated $40K sold.

Zurich Cantonal Bank first reported a position in AVIR in Q2 2021 and held it in 8 quarters. The position peaked at $98K in Q3 2021. 133 funds tracked by Wall St. Rank hold AVIR as of Q2 2023.

  • Zurich Cantonal Bank reported no remaining Atea Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Zurich Cantonal Bank sold 11,955 Atea Pharmaceuticals shares in Q2 2023, an estimated $40K.
  • Zurich Cantonal Bank first reported a position in Atea Pharmaceuticals in Q2 2021 and held it in 8 quarters.
  • Zurich Cantonal Bank's Atea Pharmaceuticals position peaked at $98K in Q3 2021.
  • 133 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2023.

Based on Zurich Cantonal Bank's 13F filing for Q2 2023, filed 7 Aug 2023.